Walid Kamoun, Vice President, Global Head of RandD Oncology at Servier, shared a post by Chris Spivey, Director of Industry Relations and Strategic Partnerships at MJH Life Sciences, adding:
“Recently, I had the opportunity to join Behind the Headlines podcast for a thoughtful discussion on JPM26, the future of precision oncology, contribution of AI, what’s making progress and where we still need to push harder as an industry.
From my perspective, progress will come from a few critical levers:
- Precision medicine, especially in areas like brain tumors where biology is highly heterogenous and matching the right therapy to the right patient is critical to hope for transformative clinical benefit.
- Partnerships and platforms that help us tackle scientific hurdles – including AI-enabled drug discovery and more importantly AI-enabled clinical development
- Global collaboration, ensuring innovation can emerge anywhere and reach patients everywhere
At Servier, our focus is on combining strong internal RandD with external innovation whether through strategic AI collaborations (we signed two since the beginning of the year), early-stage biotech engagement (we partnered with three last year), or new approaches to clinical trial access in rare cancers.
Many thanks to Chris Spivey for hosting and for the insightful discussion and thanks to Alex Philippidis for the great conversation.”
Quoting Chris Spivey‘s post:
“Industry Direction after JPM
BTH EP#32 live.
Walid Kamoun and Alex Philippidis discuss AI’s Power to Lower Costs while Elucidating Tumor Progression. NVIDIA and Eli Lilly and Company’s $1B 5 year Deal, Revolution Medicines Medicine’s lack of a Deal. It was lovely also to conjure up Merrimack Michael Cardone and nanotherapeutics, in conversation.
In the wake of the book-end jpm2026 in San Francisco—examine the fast-changing landscape of manufacturing re-shoring, research budget cuts, and the consistent migration of AI approach from fear of missing out, or FOMO, a few years back to practical implementation and return on investment in commercial manufacturing and clinical trial settings.
Reflecting on the signals emanating from JPM, there appears to be a shift in the JPM landscape in the departure of almost all major payers, such as Centene Corporation, Cigna Healthcare, and Humana, among others. In fact, the only payers present this year were Alignment Healthcare and Clover Health, two small insurance tech companies. None of the for-profit health systems were on site either. Overall, a “get comfortable with uncertainty” mantra framed a modestly optimistic outlook.
Patent cliff exigencies fueled high expectations for deals, but apart from the $1Billion, 5-year NVIDIA-Eli Lilly launch of an AI co-innovation lab to reinvent drug discovery,1 silence was the loudest message, especially in regard to a highly anticipated Merck acquisition of Revolution Medicines (up to $30B) for its cancer drug, daraxonrasib
Thanks to our experts Walid Kamoun global head of RandD Oncology, Servier, and Alex Philippidis, senior business editor, Genetic Engineering and Biotechnology News Inside Precision Medicine and Mary Ann Liebert, Inc , also BioPharm International MJH Life Sciences.”
Other articles featuring Walid Kamoun.